GlassScriptPhysician profile
Jaime A Alvarez
NPI 1013904457
$1,114.54
in general payments reported to CMS, 2019-2025
14 companies · $90.38 in 2025
The $90.38 reported for 2025 was more than what a typical Emergency Medical Services provider received nationally (typical 2025 total: $70.35).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $57.79 · 2021: $186 · 2022: $206 · 2023: $244 · 2024: $168 · 2025: $90.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $482 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $482.33 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $240.40 | 2022-2024 | Brilinta, Andexxa |
| Csl Behring | $193.71 | 2020-2024 | Kcentra, Hizentra |
| Genentech USA, INC. | $170.55 | 2019-2020 | |
| Pfizer INC. | $137.88 | 2019-2025 | |
| Glaxosmithkline, LLC. | $115.70 | 2021-2022 | |
| Ucb, INC. | $59.95 | 2022-2023 | Nayzilam |
| Octapharma USA, INC. | $47.22 | 2024 | Balfaxar |
| Janssen Pharmaceuticals, INC | $45.68 | 2020-2023 | Xarelto |
| Kedrion Biopharma, INC. | $23.47 | 2025 | Albuked, Rhogam Ultra-Filtered Plus, Gammaked |
| Melinta Therapeutics, LLC | $19.52 | 2023 | Orbactiv, Kimyrsa |
| Ambu INC. | $17.81 | 2022 | |
| Gilead Sciences, INC. | $15.89 | 2024 | |
| Djo, LLC | $13.85 | 2021 | |
| Chiesi USA, INC. | $12.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.